B-cell Immunity in MS

International MS Journal

Volumn 10, Issue 4, 2003, Pages 110-120

  Qin, Y ^a   Duquette, P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

Antigen driven response; B cell clonal expansion; Central nervous system; Humoral immunity; Immune response

Indexed keywords

AUTOANTIBODY; COMPLEMENT; IMMUNOGLOBULIN; MEMBRANE ANTIGEN; MYELIN;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOIMMUNITY; B LYMPHOCYTE; CELLULAR IMMUNITY; CEREBROSPINAL FLUID; CLONAL EXPANSION; CLONOGENESIS; COMPLEMENT ACTIVATION; DEGENERATIVE DISEASE; DEMYELINATION; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN GENE; IMMUNOLOGICAL MEMORY; IMMUNOPATHOGENESIS; INFLAMMATION; LYMPHOCYTE CLONE; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; SOMATIC HYPERMUTATION; T LYMPHOCYTE; TISSUE REPAIR;

ANTIBODY FORMATION; B-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; HUMANS; IMMUNITY; MULTIPLE SCLEROSIS;

EID: 0842269849     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Poser CM. The epidemiology of multiple sclerosis: a general overview. Ann Neurol 1994; 36 (Suppl 2): S180-S193.
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
3. Lassmann H, Raine CS, Antel J, Prineas JW. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 1998; 86: 213-217.
4. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285.
5. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.
6. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995; 377: 150-151.
7. Wekerle H. The viral triggering of autoimmune disease. Nat Med 1998; 4: 770-771.
8. Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard CC, Ben-Nun A. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 1993; 92: 2602-2608.
9. Bansil S, Cook SD, Rohowsky-Kochan C. Multiple sclerosis: immune mechanism and update on current therapies. Ann Neurol 1995; 37 (Suppl 1): S87-S101.
10. Tourtellotte W. On cerebrospinal fluid immunoglobulin-G (IgG) quotients in multiple sclerosis and other diseases. A review and a new formula to estimate the amount of IgG synthesized per day by the central nervous system. J Neurol Sci 1970; 10: 279-304.
11. Esiri MM. Immunoglobulin-containing cells in multiple sclerosis plaques. Lancet 1977; 2: 478.
12. Sesboue R, Daveau M, Degos JD, Martin-Mondiere C, Goust JM, Schuller E et al. IgG (Gm) allotypes and multiple sclerosis in a French population: phenotype distribution and quantitative abnormalities in CSF with respect to sex, disease severity, and presence of intrathecal antibodies. Clin Immunol Immunopathol 1985; 37: 143-153.
13. Giles PD, Wroe SJ. Cerebrospinal fluid oligoclonal IgM in multiple sclerosis: analytical problems and clinical limitations. Ann Clin Biochem 1990; 27: 199-207.
14. Lolli F, Siracusa G, Amato MP, Fratiglioni L, Dal Pozzo G, Galli E et al. Intrathecal synthesis of free immunoglobulin light chains and IgM in initial multiple sclerosis. Acta Neurol Scand 1991; 83: 239-243.
15. Cole SR, Beck RW, Moke PS, Kaufman DI, Tourtellotte WW. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group. Neurology 1998; 51: 885-887.
16. Filippini G, Comi GC, Cosi V, Bevilacqua L, Ferrarini M, Martinelli V et al. Sensitivities and predictive values of paraclinical tests for diagnosing multiple sclerosis. J Neurol 1994; 241: 132-137.
17. Olsson T, Zhi WW, Hojeberg B, Kostulas V, Jiang YP, Anderson G et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest 1990; 86: 981-985.
18. Cross AH, Trotter JL, Lyons JA. B-cells and antibodies in CNS demyelinating disease. J Neuroimmunol 2001; 112: 1-14.
19. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5: 170-175.
20. Horikawa Y, Tsubaki T, Nakajima M. Rubella antibody in multiple sclerosis. Lancet 1973; 1: 996-997.
21. Oger J, Roos R, Antel JP. Immunology of multiple sclerosis. Neurol Clin 1983; 1: 655-679.
22. Qin YF, Duquette P, Zhang YP, Talbot P, Poole R, Antel J. Clonal expansion and somatic hypermutation of V-H genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998; 102: 1045-1050.
23. Owens GP, Kraus H, Burgoon MP, Smith-Jensen T, Devlin ME, Gilden DH. Restricted use of V(H)4 germline segments in an acute multiple sclerosis brain. Ann Neurol 1998; 43: 236-243.
24. Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CCA, Oksenberg JR. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999; 163: 5133-5144.
25. Colombo M, Dono M, Gazzola P, Roncella S, Valetto A, Chiorazzi N et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 2000; 164: 2782-2789.
26. Cross AH. MS: the return of the B-cell. Neurology 2000; 54: 1214-1215.
27. Correale J, de Los Milagros Bassani Molinas M. Oligoclonal bands and antibody responses in multiple sclerosis. J Neurol 2002; 249: 375-389.
28. Archelos JJ, Storch MK, Hartung HP. The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 2000; 47: 694-706.
29. Vitetta ES, Berton MT, Burger C, Kepron M, Lee WT, Yin XM. Memory B and T cells. Annu Rev Immunol 1991; 9: 193-217.
30. Shlomchik MJ, Marshak-Rothstein A, Wolfowicz CB, Rothstein TL, Weigert MG. The role of clonal selection and somatic mutation in autoimmunity. Nature 1987; 328: 805-811.
31. Liu YJ, Johnson GD, Gordon J, MacLennan IC. Germinal centres in T-cell-dependent antibody responses. Immunol Today 1992; 13: 17-21.
32. Schroeder HW Jr, Hillson JL, Perlmutter RM. Structure and evolution of mammalian VH families. Int Immunol 1990; 2: 41-50.
33. Roberts S, Cheetham JC, Rees AR. Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering. Nature 1987; 328: 731-734.
34. Burnet FM. A modification of Jerne's theory of antibody production using the concept of clonal selection. CA Cancer J Clin 1976; 26: 119-121.
35. Griffiths GM, Berek C, Kaartinen M, Milstein C. Somatic mutation and the maturation of immune response to 2-phenyl oxazolone. Nature 1984; 312: 271-275.
36. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC. Mechanism of antigen-driven selection in germinal centres. Nature 1989; 342: 929-931.
37. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998; 8: 363-372.
38. Gray D, Skarvall H. B-cell memory is short-lived in the absence of antigen. Nature 1998; 336: 70-73.
39. Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996; 45: 322-333.
40. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1 alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999; 96: 6873-6878.
41. Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993; 116: 135-146.
42. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology 1997; 49: 1404-1413.
43. Paolino E, Fainardi E, Ruppi P, Tola MR, Govoni V, Casetta I et al. A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60: 572-575.
44. Soderstrom M, Ya-Ping J, Hillert J, Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998; 50: 708-714.
45. Bashir K, Whitaker JN. Importance of paraclinical and CSF studies in the diagnosis of MS in patients presenting with partial cervical transverse myelopathy and negative cranial MRI. Mult Scler 2000; 6: 312-316.
46. Zeman AZ, Kidd D, McLean BN, Kelly MA, Francis DA, Miller DH et al. A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60: 27-30.
47. Gay D, Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain 1991; 114: 557-572.
48. Loos M. Biosynthesis of the collagen-like C1q molecule and its receptor functions for Fc and polyanionic molecules on macrophages. Curr Top Microbiol Immunol 1983; 102: 1-56.
49. Bhakdi S, Tranum-Jensen J. Complement lysis: a hole is a hole. Immunol Today 1991; 12: 318-320; discussion 321.
50. Sun JB, Olsson T, Wang WZ, Xiao BG, Kostulas V, Fredrikson S et al. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 1991; 21: 1461-1468.
51. Olsson T, Baig S, Hojeberg B, Link H. Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis. Ann Neurol 1990; 27: 132-136.
52. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
53. Compston DA, Morgan BP, Campbell AK, Wilkins P, Cole G, Thomas ND et al. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 1989; 15: 307-316.
54. Sellebjerg F, Jaliashvili I, Christiansen M, Garred P. Intrathecal activation of the complement system and disability in multiple sclerosis. J Neurol Sci 1998; 157: 168-174.
55. Morgan BP, Gasque P. Expression of complement in the brain: role in health and disease. Immunol Today 1996; 17: 461-466.
56. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody-and complement-mediated demyelination. Ann Neurol 1998; 43: 465-471.
57. Adams CW. The onset and progression of the lesion in multiple sclerosis. J Neurol Sci 1975; 25: 165-182.
58. Prineas JW, Kwon EE, Cho ES, Sharer LR, Barnett MH, Oleszak EL et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001; 50: 646-657.
59. Gilden DH, Burgoon MP, Kleinschmidt-DeMasters BK, Williamson RA, Ghausi O, Burton DR et al. Molecular immunologic strategies to identify antigens and b-cell responses unique to multiple sclerosis. Arch Neurol 2001; 58: 43-48.
60. Williamson RA, Burgoon MP, Owens GP, Ghausi O, Leclerc E, Firme L et al. Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc Natl Acad Sci U S A 2001; 98: 1793-1798.